<DOC>
	<DOC>NCT01644500</DOC>
	<brief_summary>The purpose of this study is to examine if once-weekly dulaglutide is efficient and safe compared to glimepiride in participants with type 2 diabetes mellitus who have inadequate glycemic control with oral antihyperglycemic medication (OAM) or are OAM-naïve.</brief_summary>
	<brief_title>A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Dulaglutide</mesh_term>
	<mesh_term>Immunoglobulin Fc Fragments</mesh_term>
	<criteria>Type 2 diabetes mellitus OAMnaïve or have been taking OAM monotherapy for at least 3 months Glycosylated Hemoglobin (HbA1c) value of ≥7.0% to ≤10.5% for OAMnaïve participants or ≥6.5% to ≤10.0% for participants taking OAM monotherapy Adult men or adult nonpregnant, nonbreastfeeding women Stable weight (±5%) ≥3 months prior to screening Body mass index (BMI) of ≥19.0 to ≤35.0 kilograms per square meter (kg/m^2) Have type 1 diabetes mellitus Have previously been treated with a glucagonlike peptide1 (GLP1) receptor agonist, GLP1 analog, or any other incretin mimetic during the 3 months before screening Are currently taking dipeptidylpeptidaseIV (DPPIV) inhibitor and thiazolidinediones (TZD) during the 3 months before screening Have gastric emptying abnormality Have cardiac disorder defined as unstable angina, myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary intervention, heart failure, arrhythmia, transient ischemic attack, or stroke Have poorly controlled hypertension (systolic blood pressure above 160 millimeters of mercury [mmHg] or diastolic blood pressure above 95 mmHg) Have impaired liver function Have impaired kidney function Have history of chronic pancreatitis or acute pancreatitis Have a serum calcitonin ≥20 picogram/milliliter (pg/mL) Have a personal or family history of medullary Ccell hyperplasia, focal hyperplasia, carcinoma or multiple endocrine neoplasia type 2 (MEN 2)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>